ArticleFrontiers in pharmacology2026
Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the distinct clinical manifestations of chemotherapy-induced peripheral neuropathy (CIPN) in patients with different types of lung cancer treated with docetaxel or nab-paclitaxel, as well as to evaluate the post-intervention symptom improvement following therapeutic management. Methods: This prospective cohort study was conducted from September 2024 to August 2025 across two medical centers in China. Participants were lung cancer patients who had received treatment with either docetaxel or nab-paclitaxel. Chemotherapy-induced peripheral neuropathy (CIPN) was assessed using patient-reported outcomes from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). Multivariable regression models were adjusted for patient baseline characteristics, tumor status, and medication-related features. Evaluations were performed using overlap propensity score weighting. Data analysis was carried out from September 2025 to December 2025. Results: Among the 850 participants, the mean (SD) age was 63.2 (10.5) years, with 385 patients (45.3%) receiving docetaxel and 465 patients (54.7%) receiving nab-paclitaxel. The docetaxel group primarily reported motor symptoms (e.g., leg weakness: 92 patients [34.2%]) and autonomic symptoms (e.g., blurred vision: 108 patients [40.1%]). In contrast, the nab-paclitaxel group predominantly reported sensory symptoms, such as numbness in the hands and feet (68 patients [25.3%]). The onset of patient-reported motor symptoms occurred earlier than sensory abnormalities, with median times of 2.3 weeks (95% CI, 1.3-5.4) in the docetaxel group and 0.8 weeks (95% CI, 0.6-1.2) in the nab-paclitaxel group. After adjustment using overlap propensity score weighting, patients in the docetaxel group had a lower risk of reported CIPN compared to those in the nab-paclitaxel group (HR, 0.65 [95% CI, 0.54-0.86]; Conclusion: In this cohort study of lung cancer patients, nab-paclitaxel was associated with more severe CIPN compared to docetaxel, regardless of patients' clinical characteristics. Multivariate analysis identified taxane type, number of prior treatment cycles, treatment phase, and the use of pregabalin for intervention as independent factors associated with patient-reported CIPN. These findings may contribute to early intervention and therapeutic decision-making for CIPN during taxane-based treatment of lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.